Supplementary Figure S6 from Phase I/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent/Refractory Malignancies: Arm D of the AcSé-ESMART Trial
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Comparison of Homologous Recombination Deficiency (HRD) Scores and Tumor Mutational Burden (TMB) Between Treatment Responders and Non-Responders.
Fields of Study & Subjects
PARP inhibition in cancer therapy
BRCA gene mutations in cancer
Acute Lymphoblastic Leukemia research
Publication details
- Publication date
- 1 April 2026
- Language
- EN